Sign In
Buy ERAS
$18.53
-0.650 (-3.39%)
At Close: Jul 10, 2026
Erasca to Present at the Bank of America Securities Health Care Conference
08:00am, Wednesday, 06'th May 2026
SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for pa
Erasca, Inc. Investors Should Contact Block & Leviton LLP to Learn More About Securities Fraud Investigation
06:02pm, Monday, 04'th May 2026
Investors who lost money in Erasca Inc. (Nasdaq: $ERAS) should contact Block & Leviton to potentially recover losses via securities fraud investigation.
Buy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash Runways
11:07am, Monday, 04'th May 2026
Clinical-stage biotech is one of the few corners of the market where a sub-$30 share price genuinely matters: small-cap oncology names can re-rate violently around a single Phase 3 readout or FDA deci
SHAREHOLDER ALERT: Erasca, Inc. Investigated for Securities Fraud Violations by Block & Leviton
04:08pm, Friday, 01'st May 2026
Boston, Massachusetts--(Newsfile Corp. - May 1, 2026) - Block & Leviton is investigating Erasca, Inc. (NASDAQ: ERAS) for potential securities law violations. Investors who have lost money in their Era
Erasca Shares Phase 1 ERAS-0015 Data: 62% NSCLC Response, ctDNA Clearance Signals
02:21pm, Wednesday, 29'th Apr 2026
Erasca (NASDAQ: ERAS) presented a preliminary Phase 1 data update for ERAS-0015 (also referred to as ERAS-15), which management described as a "pan-RAS molecular glue," highlighting early signals of e
Erasca, Inc. ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses
12:22pm, Wednesday, 29'th Apr 2026
Boston, Massachusetts--(Newsfile Corp. - April 29, 2026) - Block & Leviton is investigating Erasca, Inc. (NASDAQ: ERAS) for potential securities law violations. Investors who have lost money in their
Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial
04:59pm, Tuesday, 28'th Apr 2026
Today, April 28, 2026, investors are weighing how a trial death will reshape Erasca's investment thesis.
Erasca Stock Sinks 50% in Race for ‘Miracle' Cancer Drug. What's Behind the Historic Sell-Off.
12:29pm, Tuesday, 28'th Apr 2026
Erasca is developing a competitor to Revolution Medicines' daraxonrasib.
SAN DIEGO, April 28, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Erasca, Inc. (NASDAQ: ERAS). The investigation focuses on Erasca's execut
Erasca, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors to Contact the Firm to Possibly Recover Losses
10:17am, Tuesday, 28'th Apr 2026
Block & Leviton is investigating Erasca Inc. ($ERAS) for possible securities fraud. Investors who lost money should contact the firm to recover losses.
Why Is Cancer Drug Developer Erasca Stock Plunging On Tuesday?
09:19am, Tuesday, 28'th Apr 2026
Erasca Inc. (NASDAQ:ERAS) said it intends to vigorously contest allegations made by Revolution Medicines, Inc. (NASDAQ:RVMD).
Erasca shares sink after patient death in early-stage cancer drug trial
06:13am, Tuesday, 28'th Apr 2026
Erasca shares fell over 35% before the bell on Tuesday after the company disclosed a patient death in an early-stage trial of its experimental cancer drug, even though analysts said the incident
Erasca, Inc. (ERAS) Discusses Preliminary Phase I Data and Differentiation of Pan-RAS Molecular Glue ERAS-0015 Transcript
10:51pm, Monday, 27'th Apr 2026
Erasca, Inc. (ERAS) Discusses Preliminary Phase I Data and Differentiation of Pan-RAS Molecular Glue ERAS-0015 Transcript
Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for
